Four and One-Half-Year Follow-up of the Effectiveness of Diphtheria-Tetanus Toxoids-Acellular Pertussis/Haemophilus influenzae Type b and Diphtheria-Tetanus Toxoids-Acellular Pertussis-Inactivated Poliovirus/H. influenzae Type b Combination Vaccines in Germany
- 1 October 2004
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 23 (10) , 944-950
- https://doi.org/10.1097/01.inf.0000141743.74443.73
Abstract
Recently an increase in the number of invasive Haemophilus influenzae type b (Hib) cases was observed in the United Kingdom, which coincided with a temporary change from diphtheria-tetanus toxoids-wild-type pertussis to diphtheria-tetanus toxoids-acellular pertussis (DTaP) Hib vaccines. A study in Germany based on approximately 2 years of follow-up, estimated vaccine effectiveness (VE) of DTaP/Hib and DTaP-inactivated poliovirus/Hib combination vaccines against invasive Hib disease to be high. To assess VE of DTaP-containing Hib vaccines against Hib in Germany with the use of extended follow-up of case surveillance and vaccine uptake. Cases with confirmed systemic Hib infections in children born between June 1, 1996 and December 31, 1998 were ascertained by a nationwide active surveillance system from January 1998 through June 2002. A representative subcohort of 667 children born in the same time frame was randomly sampled in a nationwide vaccine coverage survey. VE was determined with a case-cohort approach of Cox regression with time-dependent covariates. Thirty-six cases of Hib disease were reported. Of these, 10 were vaccinated with DTaP-containing Hib vaccines only and 20 were not vaccinated. Of the 10 vaccinated cases, 4 had received an incomplete primary series (1–2 doses), and 6 had received the full primary series (3 doses), 3 of whom also received the booster dose. VE of combination vaccines against invasive Hib infection was 89.6% [95% confidence interval (CI), 67.0–96.7] for an incomplete primary series, 96.7% (95% CI 87.7–99.1) for a full primary series and 98.5% (95% CI 94.5–99.6) for a booster dose (irrespective of priming). Hib combination vaccines containing acellular pertussis antigens continue to be highly effective in Germany.Keywords
This publication has 21 references indexed in Scilit:
- EstimatingHaemophilus influenzaeType b Vaccine Effectiveness in England and Wales by Use of the Screening MethodThe Journal of Infectious Diseases, 2003
- Return of Haemophilus influenzae type b infectionsThe Lancet, 2003
- Impact of meningococcal C conjugate vaccine in the UKJournal of Medical Microbiology, 2002
- Haemophilus influenzae Type b Vaccine: Reconstitution of Lyophilised PRP-T Vaccine with a Pertussis-containing Paediatric Combination Vaccine, or a Change in the Primary Series Immunisation Schedule, May Modify the Serum Anti-PRP Antibody ResponsesCurrent Medical Research and Opinion, 2001
- Pädiatrische Epidemiologie in Deutschland: Forschungsinstrument ESPED (Erhebungseinheit für seltene pädiatrische Erkrankungen in Deutschland)Monatsschrift Kinderheilkunde, 2001
- Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussisThe Lancet, 1999
- Evidence for induction of polysaccharide specific B-cell-memory in the 1st year of life: plain Haemophilus influenzae type b - PRP (Hib) boosters children primed with a tetanus-conjugate Hib-DTPa-HBV combined vaccineEuropean Journal of Pediatrics, 1996
- Changing patterns of invasive Haemophilus influenzae disease in England and Wales after introduction of the Hib vaccination programmeBMJ, 1996
- Estimation of Vaccine Effectiveness Using the Screening MethodInternational Journal of Epidemiology, 1993
- A case-cohort design for epidemiologic cohort studies and disease prevention trialsBiometrika, 1986